16:02 Dec 20
Themis Medicare Ltd.
Sector Pharmaceuticals & Biotechnology
Industry Pharmaceuticals
Themis Medicare Ltd.
Industry Pharmaceuticals
16:02 Dec 20
Quality
34/100
Low Financial Strength
Valuation
23/100
Expensive Valuation
Technical
53/100
Technically Neutral
Strength
2
Weakness
10
Opportunity
1
Threats
0
11.52 %
ROE %
7.68 %
ROA %
5.76
EPS
41.03
BVPS
11.40 %
Net Profit Margin
| Mar 2023 | Mar 2024 | TTM 2024 | ||
|---|---|---|---|---|
| Net Sales | 354.32 | 381.76 | 420.33 | |
| Operating Expenses + | 286.88 | 330.25 | 356.66 | |
| Raw Material | 126.16 | 138.28 | 152.12 | |
| Increase Decrease in Cost | -7.79 | -1.57 | -3.52 | |
| Other Manufacturing Expense | 0 | 0 | 0 | |
| Employee Cost | 66.15 | 82.41 | 88.36 | |
| Miscellaneous Expenses | 162.6 | 218.35 | 119.7 | |
| Operating Profit | 67.44 | 51.51 | 63.67 | |
| Other Income | 11.5 | 4.76 | 3.76 | |
| Depreciation | 10.49 | 12.25 | 11.02 | |
| Interest | 9.56 | 9.38 | 9.64 | |
| Profit before tax and exceptio.. | 58.9 | 34.64 | 46.77 | |
| Exceptional Items | 0 | 0 | 0 | |
| PBT | 58.9 | 34.64 | 46.77 | |
| Provision for Taxation | 15.61 | 9.92 | 13.12 | |
| Net Profit | 43.28 | 24.72 | 33.65 | |
| NET Profit after MI | 56.9 | 43.52 | 52.98 | |
| EPS | 61.83 | 4.73 | 5.75 | |
| Operating Profit Margin (%) | 19.03 | 13.49 | 15.15 | |
| Net Profit Margin (%) | 16.06 | 11.4 | 12.6 |
ShareHolding
Promoter
FII
Public
Mutual Funds
Other Institutions
All Data in Percentage (%)
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Promoter | 67.20 | 67.20 | 67.20 | 67.20 | 67.20 |
| FII | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| MF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 32.70 | 32.80 | 32.80 | 32.80 | 32.80 |
| Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shareholder | Shares | Holding % |
|---|
Download Our App On:
